Dr. Christophe Arbet-Engels talks about the empagliflozin studies and the ongoing safety program to identify any safety and side-effect concerns. However, despite reported potential urinary tract and genital infection issues, the large majority of patients of the study's 14,000 participants didn't observe any of these effects.

Dr. Christophe Arbet-Engels talks about how empagliflozin differs from other SGLT-2 inhibitors already on the market such as canagliflozin and dapagliflozin, stating that empagliflozin is “very specific” to its target, but hasn’t yet been compared to the others so it is too early to tell what other differences there might be. …

  Robert E. Ratner, MD, talks about the best way to screen for prediabetes, and the importance of balancing convenience and specificity.  

Robert E. Ratner, MD, talks about how the ADA is working to identify prediabetes and delay the onset as much as possible of diabetes. He explains that screening is extremely important and that this process also provides an opportunity for intervention. He also emphasizes that lifestyle modification is the first step …